Prize at Biennial Conference of the International Society of Hypertension, Seoul, South Korea, September 2016.

08 Nov 2016

At the end of September, Sarah-Jo Sinnott travelled to Seoul, South Korea to attend and present at the International Society of Hypertension conference. This society has members from all over the world, and the biennial conference provides a forum for the presentation and discussion of all research relating to hypertension, from basic science to clinical science to epidemiological science.

sarah-jo-sinnott_korea-1Sarah-Jo’s abstract had scored highly in the submission stages earlier in the year, and based on that she presented in the Best Oral Presentation category. In this category, researchers presented on clinical trials, biomarker studies and observational epidemiological studies. Her research was a systematic review and meta-analysis of studies that examined the comparative effectiveness of 4th line agents in Resistant Hypertension. The presentation went quite well, with interesting questions from the audience on how individual studies account for adherence to medicines in individuals with Resistant Hypertension. We were delighted to find out the next day that Sarah-Jo was awarded the Silver Prize and $700 for her presentation.  Huge thanks to all the co-authors Drs Ian Douglas, Rohini Mathur, Katherine Mansfield, Adrian Root, Laurie Tomlinson and Prof Liam Smeeth.

The conference was jam-packed with sessions on the most recent developments in hypertension research and treatment. Central amongst the discussed topics was the recent SPRINT trial – which assessed which blood pressure targets (<140mmHg or <120mmHg) are associated with improvements in cardiovascular morbidity and mortality. It appears that there is some discordance amongst leading experts whether the trial results should be accepted and used to guide the treatment of hypertension. Despite some apparent differences in opinion, there was absolute agreement that more research is required to explore optimal BP targets for older individuals with diabetes and kidney disease. Further, the point was made that while finding optimal targets is most worthwhile, it is also worth remembering that ofsarah-jo-sinnott_korea-2 the almost 1 billion people in the world with hypertension, almost 50% of these typically have uncontrolled hypertension. This has huge implications for the number of strokes and heart attacks occurring at the population level. It would be more beneficial in terms of morbidity and mortality reductions at the population level to help these people control their hypertension rather than concentrate on lower targets.

References:

  • Sinnott, S-J., Tomlinson L, Root A, Mathur R, Mansfield K, Smeeth L, Douglas I. (2016) “Comparative effectiveness of 4th line anti-hypertensive agents in resistant hypertension; A systematic review and meta-analysis”. Accepted September 2016 European Journal of Preventive Cardiology.
  • SPRINT Research Group. “A randomized trial of intensive versus standard blood-pressure control.” N Engl J Med373 (2015): 2103-2116.